Cancer Targeted Gene and Drug Delivery Nanosystems

Dear Colleagues,

Nanotechnology-based systems have shown that they can greatly contribute to the development of novel and successful antitumor strategies, offering higher therapeutic efficacy and fewer side effects than conventional approaches. In fact, nanosystems, namely targeted nanosystems, have the ability to both passively (in the case of solid tumors) and actively accumulate in tumors, due to the enhanced permeation and retention (EPR) effect and the incorporation of target moieties in nanocarriers, respectively. Thus, targeted nanosystems may allow the specific delivery of therapeutic agents in target cells, avoiding their release in the non-target ones. Moreover, nanosystems facilitate the development of innovative multitarget therapeutic strategies in a single nanoplatform, allowing the specific and simultaneous delivery of different therapeutic agents, such as drugs and genetic material, in target cells, increasing antitumor efficiency and reducing secondary effects.

This Special Issue aims to highlight the recent developments in cancer-targeted genes and drug delivery nanosystems. I would like to invite you to submit your original papers or reviews on the design, development, characterization, and application of drug and/or gene delivery nanosystems.

Dr. Henrique Faneca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• drug delivery
• gene delivery
• targeted-nanosystems
• gene therapy
• chemotherapy
• cancer nanomedicine